Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

Literature DB >> 19300883

Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

C Wischik¹, R Staff.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2009 PMID： 19300883 DOI： 10.1007/s12603-009-0046-5

Source DB: PubMed Journal: J Nutr Health Aging ISSN： 1279-7707 Impact factor: 4.075

× No keyword cloud information.

23 in total

1. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study.

Authors: W Jagust; R Thisted; M D Devous; R Van Heertum; H Mayberg; K Jobst; A D Smith; N Borys
Journal: Neurology Date: 2001-04-10 Impact factor: 9.910

2. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

Authors: G Chételat; B Desgranges; V de la Sayette; F Viader; F Eustache; J-C Baron
Journal: Neurology Date: 2003-04-22 Impact factor: 9.910

3. Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease.

Authors: E B Mukaetova-Ladinska; F Garcia-Siera; J Hurt; H J Gertz; J H Xuereb; R Hills; C Brayne; F A Huppert; E S Paykel; M McGee; R Jakes; W G Honer; C R Harrington; C M Wischik
Journal: Am J Pathol Date: 2000-08 Impact factor: 4.307

4. Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials".

Authors: Paul S Aisen
Journal: Alzheimers Dement Date: 2006-10 Impact factor: 21.566

5. Independent accumulations of tau and amyloid beta-protein in the human entorhinal cortex.

Authors: T Katsuno; M Morishima-Kawashima; Y Saito; H Yamanouchi; S Ishiura; S Murayama; Y Ihara
Journal: Neurology Date: 2005-02-22 Impact factor: 9.910

6. Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT.

Authors: Soichiro Shimizu; Haruo Hanyu; Hidekazu Kanetaka; Toshihiko Iwamoto; Kiyoshi Koizumi; Kimihiko Abe
Journal: Dement Geriatr Cogn Disord Date: 2005-04-12 Impact factor: 2.959

7. Quantitative SPECT leads to improved performance in discrimination tasks related to prodromal Alzheimer's disease.

Authors: Georges El Fakhri; Marie Foley Kijewski; Marilyn S Albert; Keith A Johnson; Stephen C Moore
Journal: J Nucl Med Date: 2004-12 Impact factor: 10.057

8. Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease.

Authors: Marta Encinas; Ramón De Juan; Alberto Marcos; Pedro Gil; Ana Barabash; Cristina Fernández; Carmen De Ugarte; José Antonio Cabranes
Journal: Eur J Nucl Med Mol Imaging Date: 2003-08-15 Impact factor: 9.236

9. Heterogeneity of cerebral blood flow in frontotemporal lobar degeneration and Alzheimer's disease.

Authors: Michinobu Nagao; Yoshifumi Sugawara; Manabu Ikeda; Ryuji Fukuhara; Kazuhiko Hokoishi; Kenya Murase; Teruhito Mochizuki; Hitoshi Miki; Takanori Kikuchi
Journal: Eur J Nucl Med Mol Imaging Date: 2004-02 Impact factor: 9.236

10. Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography.

Authors: H Matsuda; S Mizumura; T Nagao; T Ota; T Iizuka; K Nemoto; N Takemura; H Arai; A Homma
Journal: AJNR Am J Neuroradiol Date: 2007-04 Impact factor: 3.825

39 in total

Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

1. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study.

2. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

3. Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease.

4. Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials".

5. Independent accumulations of tau and amyloid beta-protein in the human entorhinal cortex.

6. Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT.

7. Quantitative SPECT leads to improved performance in discrimination tasks related to prodromal Alzheimer's disease.

8. Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease.

9. Heterogeneity of cerebral blood flow in frontotemporal lobar degeneration and Alzheimer's disease.

10. Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography.

Review 1. Tau-targeted treatment strategies in Alzheimer's disease.

Review 2. Current therapeutic targets for the treatment of Alzheimer's disease.

3. Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice.

4. Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease.

Review 5. [Diagnosis without therapy: early diagnosis of Alzheimer's disease in the stage of mild cognitive impairment].

Review 6. Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.

7. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo.

8. Soluble forms of tau are toxic in Alzheimer's disease.

Review 9. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.

Review 10. Alzheimer disease therapy--moving from amyloid-β to tau.